chufangao/CTO huggingface dataset:
Clinical trial NCT03901378: Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma
Official title: A Phase II Trial of Pembrolizumab in Combination With Cisplatin or Carboplatin and Etoposide in Chemotherapy naïve Patients With Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung (Excluding Small Cell) Neuroendocrine Carcinoma
Sponsor: Ochsner Health System (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Lack of accrual
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-10-02
Primary completion date: 2021-01-21
Completion date: 2021-01-21
Plan to share individual participant data: NO
Clinical trial NCT01243476: Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome
Official title: Multicenter, Randomized, Double-blind, Phase III Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) With Alteration in 5q- and Anemia Without the Need of Transfusion.
Acronym: SINTRA-REV
Sponsor: Fundación General de la Universidad de Salamanca (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 61.0 (ACTUAL)
Number of arms: 2.0
Start date: 2010-01-31
Primary completion date: 2022-06-06
Completion date: 2022-06-06
Clinical trial NCT03008512: A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib
Official title: A Phase II Study of Weekly Genexol-PM in Patients With Advanced Hepatocelluar Carcinoma After Failure of Sorafenib
Sponsor: Gachon University Gil Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Poor accrual
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-10-31
Primary completion date: 2021-02-28
Completion date: 2021-02-28
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03338816: ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)
Official title: ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study With an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyrias
Sponsor: Alnylam Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 94.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-11-16
Primary completion date: 2019-01-31
Completion date: 2021-05-31
Baseline population: Safety Analysis Set (SAS) consisted of all participants who received at least one dose of study drug.
Plan to share individual participant data: YES
IPD sharing description: Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU.~Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Requests for access to data can be submitted via the website www.vivli.org.
Clinical trial NCT03906838: Regional Anesthesia Block in Fibula Free Flap Reconstruction
Official title: Does Regional Anesthesia Reduce Postoperative Opioid Consumption in Subjects Undergoing Fibula Free Flap Reconstruction of the Head and Neck: A Prospective Trial
Sponsor: University of Florida (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: funding not obtained
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-01
Primary completion date: 2020-11-30
Completion date: 2020-11-30
Plan to share individual participant data: NO
Clinical trial NCT04649710: A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean Participants
Official title: A Double-Blind, Multicenter, Placebo-Controlled, Randomized, Parallel, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean Participants
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Business objectives have changed
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-06-21
Primary completion date: 2021-09-21
Completion date: 2021-09-22
Clinical trial NCT05065619: Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19）
Official title: A Phase I/II, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of MT-2766 in Japanese Adults (COVID-19)
Sponsor: Medicago (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Public vaccination of approved ancestral strain COVID-19 vaccines will be terminated soon. And boosters must be dosed after ancestral vaccination approved in Japan. The study was terminated for ethical reason to prioritize the ancestral vaccination.
Enrollment: 128.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-10-02
Primary completion date: 2022-03-12
Completion date: 2023-01-29
Baseline population: Safety population included all randomized subjects who received at least 1 dose of the investigational product.~After randomization, one subject withdrew before receiving investigational product at the subject's request.
Plan to share individual participant data: NO
Clinical trial NCT04965714: Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer
Official title: A Pre-Operative Study Evaluating Nivolumab Plus ADI-PEG 20 in Patients With Resectable Hepatocellular Carcinoma
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: 0 patient accrual
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-04-13
Primary completion date: 2023-02-10
Completion date: 2023-02-10
Clinical trial NCT05652660: A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults
Official title: AN INTERVENTIONAL, PHASE 1, OPEN-LABEL, FIXED-SEQUENCE, 2-PERIOD STUDY TO EVALUATE THE EFFECT OF A SINGLE ORAL DOSE OF ARV-471 (PF-07850327) ON THE PHARMACOKINETICS OF ROSUVASTATIN IN HEALTHY PARTICIPANTS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-12-09
Primary completion date: 2023-02-09
Completion date: 2023-03-06
Baseline population: The baseline analysis population defined as all participants enrolled and who took at least 1 dose of study intervention.
Plan to share individual participant data: NO
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT01119417: The Role of Endothelin in the Supine Hypertension of Autonomic Failure
Official title: The Role of Endothelin in the Supine Hypertension of Autonomic Failure
Sponsor: Vanderbilt University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: No participants were enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2010-05-31
Primary completion date: 2021-05-31
Completion date: 2021-05-31
Plan to share individual participant data: NO
Clinical trial NCT02957305: Misoprostol 400 µg Versus 200 µg for Cervical Ripening in 1st Trimester Miscarriage
Official title: Comparison Between 400 µg or 200 µg of Misoprostol for Cervical Dilatation in 1st Trimester Miscarriage - A Clinical Trial
Acronym: MISO200
Sponsor: Hospital de Clinicas de Porto Alegre (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 211.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-12-21
Primary completion date: 2019-10-19
Completion date: 2020-06-30
Limitations and caveats: Technical problems with measurement leading to unreliable. Pregnancies with less than 8 weeks had their procedures completely done with small diameter Karman cannulas
Plan to share individual participant data: YES
IPD sharing description: We intend to share raw data with other researchers
IPD time frame: unlimited
IPD access criteria: free to read
Clinical trial NCT05758298: Assessing the Use of Nicotine Gum to Decrease Betel Nut Chewing in Saipan
Official title: Assessing the Use of Nicotine Gum to Decrease Betel Nut Chewing in Saipan
Sponsor: University of Texas Southwestern Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Have not received IRB approval.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2023-10-01
Primary completion date: 2024-12-31
Completion date: 2024-12-01
Plan to share individual participant data: NO
Clinical trial NCT04632199: Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer.
Official title: A Phase I, Open Label, Study to Assess Safety, Tolerability, Biodistribution, Radiation Dosimetry and SPECT/CT Imaging Characteristics of Intravenous 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma or Colorectal Cancer.
Sponsor: Ipsen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Business decision not related to any safety or tolerability concern
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-12
Primary completion date: 2021-12-10
Completion date: 2021-12-10
Plan to share individual participant data: NO
Clinical trial NCT02601378: A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
Official title: A Phase I, Multi-center, Open-label, Study of LXS196, an Oral Protein Kinase C Inhibitor, in Patients With Metastatic Uveal Melanoma
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The combination part of the study was terminated early due to business reasons
Enrollment: 107.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-02-01
Primary completion date: 2022-01-07
Completion date: 2022-01-07
Plan to share individual participant data: NO
Clinical trial NCT04125745: Oral CXA-10 in Pulmonary Arterial Hypertension
Official title: Phase 2 Open-Label Study of Safety and Efficacy Trial of CXA-10 in Pulmonary Arterial Hypertension
Acronym: PAH
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: negative study outcome from Complexa's multicenter clinical trial; no safety concerns
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-10-31
Primary completion date: 2020-12-01
Completion date: 2020-12-01
Limitations and caveats: The clinical trial was terminated early due to lack of efficacy based on the negative study outcome from the drug company's multicenter clinical trial. Early termination leading to small numbers of subjects analyzed.
Plan to share individual participant data: YES
IPD sharing description: The PI will make individual participant data (IPD) available through a data sharing agreement. After publication, data will be deposited in all available suitable public access databases for archival purposes.
IPD time frame: Starting 6 months after publication
IPD access criteria: Through a data sharing agreement
Clinical trial NCT02165215: A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Official title: Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Acronym: LAUREL
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 359.0 (ACTUAL)
Number of arms: 3.0
Start date: 2014-08-12
Primary completion date: 2020-04-06
Completion date: 2020-04-06
Clinical trial NCT03473340: Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD)
Official title: A Phase Two Randomized, Double-blinded, Placebo-controlled Study Combining Physiological, Radiographic, and Biological Biomarkers to Study the Anti-fibrotic Effect of Pirfenidone in CLAD Post Lung-transplantation
Sponsor: University of Michigan (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow and delayed recruitment due in part to COVID, led to a decision to end funding and terminate the trial.
Enrollment: 24.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-04-27
Primary completion date: 2021-07-23
Completion date: 2021-08-20
Plan to share individual participant data: NO
Clinical trial NCT03277248: Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)
Official title: Phase III: UbLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Acronym: ULTIMATE II
Sponsor: TG Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 545.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-08-25
Primary completion date: 2020-08-04
Completion date: 2020-11-12
Baseline population: Intention-to-treat (ITT) population consisted of all randomized participants.
Plan to share individual participant data: UNDECIDED
IPD sharing description: Data will be shared after study completion via publication.
Clinical trial NCT00703820: Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia
Official title: AML08: A Phase II Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Phase II Study Of Natural Killer Cell Transplantation In Patients With Newly Diagnosed Acute Myeloid Leukemia
Sponsor: St. Jude Children's Research Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 324.0 (ACTUAL)
Number of arms: 2.0
Start date: 2008-08-04
Primary completion date: 2017-03-30
Completion date: 2020-08-14
Clinical trial NCT03859752: TR1801-ADC in Patients With Tumors That Express c-Met
Official title: A Phase 1, Open Label, First-in-human Study of TR1801-ADC, an Antibody Drug Conjugate (ADC), in Patients With Select Solid Tumors Expressing c-Met
Sponsor: Open Innovation Partners, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: SUSPENDED 
Why stopped: Financial funds were withdrawn by investors and study was stopped
Enrollment: 15.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-08-14
Primary completion date: 2023-07-04
Completion date: 2023-12-31
Plan to share individual participant data: NO
Clinical trial NCT04349930: The CBD-IC Randomized Controlled Trial: Evaluation of Hemp Cannabidiol SuppositoRies for Pain and Urinary SymptOms in INterstitial Cystitis (CHRONIC)
Official title: The CBD-IC Randomized Controlled Trial: Evaluation of Hemp Cannabidiol SuppositoRies for Pain and Urinary SymptOms in INterstitial Cystitis (CHRONIC)
Acronym: CHRONIC
Sponsor: University of New Mexico (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Need to obtain IND approval.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-31
Primary completion date: 2022-07-31
Completion date: 2022-09-30
Plan to share individual participant data: NO
Clinical trial NCT04902885: Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients
Official title: A Randomized, Double-blind, Placebo-controlled, Multi-center Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Extensive-Stage Small Cell Lung Cancer Patients
Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 95.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-05-25
Primary completion date: 2021-12-29
Completion date: 2022-12-31
Clinical trial NCT03894540: Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours
Official title: A Phase I, Open Label, Dose Escalation and Dose Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumour Activity of IPN60090 as Single Agent and in Combination in Patients With Advanced Solid Tumours
Sponsor: Ipsen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Following an internal portfolio review, Ipsen has made the decision to terminate study D-US-60090-001. Ipsen would like to highlight that early termination was not due to any safety or tolerability issues with IPN60090
Enrollment: 22.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-03-22
Primary completion date: 2020-12-21
Completion date: 2020-12-21
Baseline population: Safety population included all participants who were exposed to (or started receiving) IPN60090.
Limitations and caveats: The study was terminated by the sponsor following an internal portfolio review during the dose escalation phase (Part A). The early termination was not due to any safety or tolerability issues with IPN60090.
Plan to share individual participant data: NO
Clinical trial NCT02227238: Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment
Official title: A Phase 3b, Randomized, Open-label Study of the Antiviral Activity and Safety of Dolutegravir Compared to Lopinavir/Ritonavir Both Administered With Dual Nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1 Infected Adult Subjects With Treatment Failure on First Line Therapy
Sponsor: ViiV Healthcare (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 627.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-12-11
Primary completion date: 2017-08-02
Completion date: 2022-02-14
Baseline population: Baseline Characteristic data are reported for members of the ITT-E Population which comprised of all participants who received at least one dose of study medication.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on ViiV's data sharing criteria can be found at: https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/
IPD time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Clinical trial NCT02911961: APAP-CYS Protein Adduct Concentrations in Patients With Liver-Directed Therapy Intended to Treat Hepatic Tumors
Official title: Serum Acetaminophen-Cysteine (APAP-CYS) Adduct Concentrations in Subjects Expected to Develop Aminotransferase Elevations With Liver-Directed Therapy Intended to Treat Hepatic Tumors
Sponsor: Denver Health and Hospital Authority (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Due to lack of enrollment and organizational desire to focus recruitment efforts on other studies.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-08-31
Primary completion date: 2021-08-31
Completion date: 2021-08-31
Plan to share individual participant data: NO
Clinical trial NCT05673889: A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy Adults
Official title: AN INTERVENTIONAL, PHASE 1, OPEN-LABEL, FIXED-SEQUENCE, 2-PERIOD STUDY TO EVALUATE THE EFFECT OF A SINGLE ORAL DOSE OF ARV-471 (PF-07850327) ON THE PHARMACOKINETICS OF DABIGATRAN IN HEALTHY PARTICIPANTS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 24.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-01-27
Primary completion date: 2023-03-15
Completion date: 2023-04-19
Baseline population: The baseline analysis population was defined as all participants enrolled and who took at least 1 dose of study intervention.
Plan to share individual participant data: NO
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT02729961: Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
Official title: A Phase I/II Open-Label Dose-Finding Study of Ceritinib Combined With Brentuximab Vedotin for Front-Line Treatment of ALK-Positive Anaplastic Large Cell Lymphoma
Sponsor: University of Washington (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Administrative closure
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-01-03
Primary completion date: 2023-07-01
Completion date: 2023-07-01
Plan to share individual participant data: NO
Clinical trial NCT01464034: A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Official title: A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Sponsor: Criterium, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Lack of enrollment
Enrollment: 136.0 (ACTUAL)
Number of arms: 1.0
Start date: 2011-11-30
Primary completion date: 2020-07-31
Completion date: 2020-07-31
Clinical trial NCT03736447: Peanut Oral Immunotherapy Study of Early Intervention for Desensitization
Official title: Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON)
Acronym: POSEIDON
Sponsor: Aimmune Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 146.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-12-27
Primary completion date: 2022-07-05
Completion date: 2022-07-05
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04263519: A Pilot Open Labeled Study of Tacrolimus in Alzheimer's Disease.
Official title: A Pilot Open Labeled Study of Tacrolimus to Assess it's Effects on Bio-markers of Mild Cognitive Impairment and Alzheimer's Disease
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Covid restrictions
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-01
Primary completion date: 2022-12-01
Completion date: 2023-01-01
Plan to share individual participant data: NO